Twelve-Month Safety and Efficacy of Inhaled Fluticasone Propionate in Children Aged 1 to 3 Years With Recurrent Wheezing
- 1 February 2004
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 113 (2) , e87-e94
- https://doi.org/10.1542/peds.113.2.e87
Abstract
Objective. Our aim was to compare the 12-month safety and efficacy of fluticasone propionate (FP) and sodium cromoglycate (SCG) in children aged 1 to 3 years with mild to moderate recurrent wheeze. Methods. The study was a randomized, parallel-group, open-label multicenter study of 625 children, aged 1 to 3 years, with recurrent wheeze randomized in a 3:1 ratio to treatment for 52 weeks with FP (100 μg twice daily) via metered-dose inhaler and Babyhaler spacer device or SCG (5 mg 4 times daily) via metered-dose inhaler and Nebuhaler spacer device, respectively. Results. There was no significant difference in mean adjusted growth rates between the 2 groups: 84.0 mm/year in the FP group versus 86.4 mm/year in the SCG group (difference FP-SCG: −2.4 mm/year; 95% confidence interval: −6.6 to 1.8). Growth comparisons were independent of age, gender, previous use of steroid, or whether measured as length and/or height. Serum and urinary cortisol concentrations showed a statistically significant suppression of 10% and 14%, respectively, but the number of patients with serum cortisol levels below the lower normal limit was reduced during the trial. Both treatments were well tolerated. The most common drug-related adverse events were cough (2% FP vs 1% SCG) and hoarseness (1% FP vs 0% SCG). One incident of cataract was observed at baseline and 1 after FP treatment; the latter had resolved after 12 months. The efficacy of FP was superior to SCG with fewer cases of symptom worsening, exacerbations, and requirements for oral steroid treatment and more symptom-free days and days without use of rescue treatment. Conclusions. Twelve months of treatment with inhaled FP (100 μg twice daily) in preschool children aged 1 to 3 years with recurrent wheeze has no effect on growth and no other clinically important side effects but is more efficacious than SCG.Keywords
This publication has 34 references indexed in Scilit:
- Response of preschool children with asthma symptoms to fluticasone propionateJournal of Allergy and Clinical Immunology, 2001
- Symptomatic adrenal insufficiency during inhaled corticosteroid treatmentArchives of Disease in Childhood, 2001
- Safety of inhaled corticosteroid therapy in young children with asthmaAnnals of Allergy, Asthma & Immunology, 2001
- Efficacy of budesonide inhalation suspension in infants and young children with persistent asthmaJournal of Allergy and Clinical Immunology, 1999
- Complement dependence of histamine release in chronic urticariaJournal of Allergy and Clinical Immunology, 1999
- Growth in asthmatic children treated with fluticasone propionateThe Journal of Pediatrics, 1998
- Ocular and vision defects in preschool children.British Journal of Ophthalmology, 1993
- Systemic activity of inhaled topical steroid in toddlers studied by knemometryActa Paediatrica, 1993
- Inhaled budesonide for chronic wheezing under 18 months of age.Archives of Disease in Childhood, 1992
- Partial sight and blindness in children of the 1970 birth cohort at 10 years of age.Journal of Epidemiology and Community Health, 1988